Keywords: ariad, updates, ap23573, trials, firm, pharmaceuticals, says

Ariad updates on AP23573 trials

Article | 19 February 2007

Print This

US firm Ariad Pharmaceuticals says that the Phase III clinical trial of oral AP23573, its novel mTOR inhibitor, will be ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in